Lisdexamfetamine Dimesylate

二甲磺酸赖右苯丙胺

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameLisdexamfetamine Dimesylate
Drug Alias Namelisdexanfetamina利右苯丙胺lisdexamfetaminum甲磺酸赖氨酸安非他命Vyvanse +[16] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionDopamine transporter antagonistsAlpha-1b adrenergic receptor antagonists
TargetsDopamine transporterAlpha-1b adrenergic receptor
Therapy Area/IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityDepressive Disorder, Major +[17] 
Global Approved IndicationsAttention Deficit Disorder with Hyperactivity
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2007/02/23
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShire Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)Humanis Saglık Anonim SirketiTakeda Pharmaceuticals USA Inc +[10] 
Inactive CompaniesShireUniversity of California IrvineUniversity At Buffalo +[9] 
Active IndicationsAttention Deficit Disorder with HyperactivityBulimia NervosaBinge-Eating Disorder +[8] 
Inactive IndicationsSchizophreniaDepressive Disorder, MajorBipolar Disorder +[9] 

Other Information

ATC CodeN06BA12
Related LinksWikipediaDrugBankKEGG